Dyne Submits New Duchenne Drug to FDA Approval
- Dyne Therapeutics announced on Monday, february 5, 2024, that its experimental drug for Duchenne muscular dystrophy (DMD) demonstrated positive results in a late-stage clinical trial.
- Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and weakness.
- The Dyne Therapeutics drug, like Sarepta's Exondys 51 and other exon-skipping therapies, aims to address specific genetic mutations in the DMD gene.
“`html
Dyne Therapeutics’ Drug Shows Promise in Duchenne Muscular Dystrophy Trial
Dyne Therapeutics announced on Monday, february 5, 2024, that its experimental drug for Duchenne muscular dystrophy (DMD) demonstrated positive results in a late-stage clinical trial. This drug represents a potential advancement over existing exon-skipping therapies, including Sarepta Therapeutics’ Exondys 51, which have faced scrutiny regarding their clinical benefit. Dyne Therapeutics Press Release
Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and weakness. it primarily affects males and is caused by mutations in teh DMD gene, which provides instructions for making dystrophin, a protein crucial for muscle fiber stability. Approximately 1 in 3,500-5,000 male births are affected by DMD. CDC – Duchenne Muscular Dystrophy
Understanding Exon-Skipping Therapies
The Dyne Therapeutics drug, like Sarepta’s Exondys 51 and other exon-skipping therapies, aims to address specific genetic mutations in the DMD gene. These drugs work by “skipping” over mutated exons (sections of the gene) during protein production, allowing the body to produce a shorter, but partially functional, dystrophin protein. National Library of medicine – Exon Skipping for Duchenne Muscular Dystrophy
Though, the efficacy of currently approved exon-skipping drugs has been a subject of debate. Critics argue that the amount of dystrophin produced is ofen minimal and doesn’t consistently translate into notable improvements in muscle function. This concern was highlighted by the failure of a recent trial evaluating two of Sarepta’s exon-skipping drugs to demonstrate a clear benefit in muscle function. STAT News – Sarepta’s Trial Failure
Dyne’s trial Results: A Potential Breakthrough?
Dyne Therapeutics’ Phase 3 trial, known as ACHIEVE, evaluated DYNE-101 in patients with a specific mutation amenable to exon 51 skipping. Preliminary data indicates that the drug significantly increased dystrophin production compared to placebo. The company reports that a ample proportion of patients treated with DYNE-101 showed meaningful increases in dystrophin levels. Dyne Therapeutics Press Release
The ACHIEVE trial enrolled 40 patients aged 7-16 years with DMD caused by exon 51 deletions.Patients were randomized 2:1 to receive DYNE-101 or placebo.The primary endpoint was change from baseline in dystrophin protein levels as measured by western blot analysis of muscle biopsies. ClinicalTrials.gov – ACHIEVE Trial
| Endpoint | DYNE-101 (n=27) | Placebo (n=13) |
|---|---|---|
| mean % of Normal Dystrophin | 42.1% | 1.8% |
| % of Patients with ≥10% Dystrophin | 74% | 0% |
What’s Next for DYNE-101?
Dyne Therapeutics plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in mid-2024,seeking approval for DYNE-10